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Lipoprotein(a) (Lp(a)) is an independent risk factor for the development of cardiovascular disease (CVD). Indeed, individuals
with plasma concentrations >20mg/dL carry a 2-fold increased risk of developing CVD, accounting for ∼25% of the population.
Circulating levels of Lp(a) are remarkably resistant to common lipid lowering therapies, and there are currently no robust
treatments available for reduction of Lp(a) apart from plasma apheresis, which is costly and labour intensive. The Lp(a) molecule is
composed of two parts, an LDL/apoB-100 core and a unique glycoprotein, apolipoprotein(a) (apo(a)), both of which can interact
with components of the coagulation cascade, inflammatory pathways, and cells of the blood vessel wall (smooth muscle cells
(SMC) and endothelial cells (EC)). Therefore, it is of key importance to determine the molecular pathways by which Lp(a) exerts
its influence on the vascular system in order to design therapeutics to target its cellular eﬀects. This paper will summarise the role
of Lp(a) in modulating cell behaviour in all aspects of the vascular system including platelets, monocytes, SMC, and EC.
1. Introduction
Elevated plasma lipoprotein(a) (Lp(a)) is an independent
risk factor for the development of cardiovascular disease
(CVD) [1]. It is synthesised and secreted by the liver
and comprises a lipid core of LDL cholesterol and apoB-
100, surrounded by a unique glycoprotein apolipoprotein(a)
(apo(a)) [2]. Apo(a) shares homology with plasminogen,
containing multiple copies of kringle 4 (KIV), one copy of
kringle 5 (KV) and an inactive protease domain. KIV is
present in numerous forms; there are single copies of KIV
type 1 and 3–10, but multiple copies of KIV type 2 which
give rise to the large variation in Lp(a) size (reviewed in
[2]). The species distribution of Lp(a) is limited to humans
and old world monkeys (a distant homolog is present in
hedgehogs) due to expression of the apo(a) gene. Therefore,
it is likely that it is the apo(a) moiety of Lp(a) that confers
its pathogenicity. Transgenic animals have been generated to
express human apo(a), or human apo(a) and apoB-100 to
aid the study of Lp(a) and in general these have confirmed
the observation that Lp(a) is atherogenic regardless of species
(reviewed in [3]).
Although Lp(a) was discovered almost 50 years ago [4]
and its influence as a cardiovascular risk factor has been
known since the 1980s [5, 6], its true physiological function
remains unknown. It is highly likely that it plays a role
in mediation of wound healing, as immunohistochemical
analysis of healing wounds stained positively for apo(a)/apoB
during the infiltration of immune cells, production of
granulation tissue, and initiation of revascularisation [7]. In
addition, a recent proteomics study determined that many
of the proteins associated with Lp(a) were involved with the
wound healing response [8].
In the absence of a defined physiological role of Lp(a), its
pathophysiological role is undoubtedly that of a prominent
risk factor for the development of CVD. Circulating levels
of Lp(a) are not significantly modified by traditional lipid-
lowering therapies [3, 9], and so alternative approaches to
target its adverse functions specifically are necessary and
may be of therapeutic value. This paper will focus on the
detrimental eﬀects of Lp(a) in the cardiovascular system
including the coagulation cascade, inflammatory pathways
and modulation of smooth muscle (SMC), and endothelial
cell (EC) behaviour within blood vessel walls.
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2. Thrombosis
Following injury to the vessel wall, platelets become activated
and trigger thrombus formation. Fibrin cross-links and
stabilises the clot; during resolution it is broken down
by plasmin to minimise vessel occlusion. Lp(a) has been
demonstrated to act as a prothrombotic factor, interfering
with clot biology at multiple levels, as follows.
2.1. Platelet Aggregation. Platelets are activated by exposure
to collagen on the surface of damaged blood vessels, leading
to secretion of dense granules to activate further platelets in
a positive feedback loop. Aggregation occurs via fibrinogen
binding to integrin αIIbβ3 on the platelet surface and clot
formation is initiated [10]. Lp(a) has been reported to aﬀect
platelet activation/aggregation induced by various agonists;
however, there is currently no clear consensus on whether it
potentiates or attenuates their eﬀects.
Evidence of Lp(a) influencing the initial activation of
platelets is scarce, although both Lp(a) and apo(a) alone have
been demonstrated to promote activation via thrombin-
receptor-activated hexapeptide (TRAP) [11]. However, the
ability of Lp(a) to directly aﬀect platelet aggregation is
much more contentious. Studies have shown that both
Lp(a) and apo(a) alone enhanced aggregation in response
to arachidonic acid and TRAP [11, 12], yet had no eﬀect
on aggregation induced by collagen or thrombin [12]. Lp(a)
had previously been demonstrated to inhibit aggregation
induced by low concentrations of collagen (4 μg/mL) [13];
however, in that case the inhibitory eﬀect was not observed
when collagen concentrations were increased to 10 μg/mL
[12]. Aggregation in response to platelet activating factor
(PAF) has also been reported to be inhibited by Lp(a) [14].
In the circulation, Lp(a) has been found associated with
PAF-acetylhydrolase (PAF-AH) [15]; however, inhibition
of platelet aggregation also occurred when PAF-AH was
removed from Lp(a) [14], indicating a dual inhibitory eﬀect
of Lp(a) on the PAF system. It is likely that the conflicting
eﬀects of Lp(a) on platelet aggregation are dependent on
both the concentration of aggregation factor, and interac-
tions and interplay of either apo(a) and apoB-100/LDL. For
example, inhibition of aggregation in response to PAF was
reportedly much more potent when apo(a) was removed
from the Lp(a) molecule [14].
The antiaggregatory eﬀects of Lp(a) may be mediated via
its interaction with integrin αIIbβ3. Integrin αIIbβ3 is nor-
mally bound by fibrinogen to promote platelet aggregation,
yet apo(a) can displace fibrinogen from the receptor [16]
thus inhibiting this process. In addition, functional eﬀects
of Lp(a) can be dependent on modifications of the Lp(a)
molecule—platelet granule secretion was altered when Lp(a)
was modified by lipid peroxidation products or acetylation
[17]. It is clear that the interaction of Lp(a) with platelets
is complex and involves a balance between Lp(a) subunit
binding, protein modifications, and the factor stimulating
platelet aggregation.
2.2. Tissue Factor Pathway. Tissue factor (TF) is a key early
component of the coagulation system leading to activation
of thrombin [18]. Treatment of monocytes with Lp(a) or
recombinant apo(a) (r-apo(a)) caused a 2-fold increase in
production and surface association of TF due to activation
of integrin αMβ2 and the nuclear factor kappa B (NFκB)
signalling cascade [19]. However, activation of TF displays
cell-type specificity as treatment of human umbilical vein
endothelial cells (HUVEC) with Lp(a) did not aﬀect TF
expression [20]. It is known that platelets express TF, and
since they are responsive to Lp(a) it would be of potential
interest to investigate the eﬀect on TF in this cell type.
In addition to promoting TF expression in monocytes,
Lp(a) may augment thrombosis further by binding and
inhibiting tissue factor pathway inhibitor (TFPI).Whilst usu-
ally exhibiting thrombolytic properties, TFPI is reportedly
inhibited by nanomolar concentrations of Lp(a) through the
apo(a) moiety. In addition, TFPI and apo(a) appear colo-
calised in SMC-rich intimal regions of human atherosclerotic
plaques, suggestive of functional eﬀects [21].
2.3. Impairment of Plasminogen Activation. Through its
homology with plasminogen, Lp(a) can inhibit the forma-
tion of active plasmin. Plasminogen is activated extracellu-
larly by a ternary complex comprising tissue plasminogen
activator (tPA), plasminogen and fibrin. Active plasmin then
dissociates from the complex and is able to activate TGFβ
and degrade fibrin within clots (Figure 1(a)). However,
in the presence of Lp(a), the apo(a) fragment has been
reported to bind to fibrin, forming a quaternary complex
that promotes a markedly reduced rate of plasminogen
activation compared with the classical ternary complex. This
interaction was dependent on both KV and the strong lysine
binding site (LBS) in KIV type 10, but did not involve
the inactive plasminogen-like protease domain [22]. Lp(a)
has been shown to compete with both plasminogen and
tPA for binding to fibrin, promoting a thrombotic state
through preventing plasmin-mediated clot lysis [23, 24]
(Figure 1(b)).
In addition to directly impairing ternary complex for-
mation, Lp(a) can also influence plasminogen activation
by associating with inhibitors of each component of the
ternary complex. Lp(a) was shown to inhibit the secretion
of tPA from EC [25, 26]; however, one other report did not
concur [20]. Although all these studies utilised the same
endothelial cell source (HUVEC), the lack of eﬀect of Lp(a)
on tPA secretion in the latter study may have been due
to the absence of serum in their experimental protocol.
In this case, a combination of transferrin, selenium, and
insulin was used in place of serum, and it may be that
cofactors within serum other than these are necessary for
this aspect of Lp(a) functionality. Irrespective of an eﬀect on
tPA secretion, Lp(a) has been reported to increase expression
of plasminogen activator inhibitor-1 (PAI-1, an inhibitor of
tPA) in HUVEC and human coronary artery EC (HCAEC)
in a protein kinase C (PKC-) dependent mechanism [20,
27]. This was further enhanced by oxidising or glycating
Lp(a) [26, 28]. A recent report determined that Lp(a) also
associates with other prothrombotic proteins including α2-
macroglobulin (a plasmin inhibitor) and serine proteinase
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Figure 1: Prothrombotic actions of Lp(a). (a) Plasminogen is activated in a ternary complex comprising fibrin and tPA. Mature plasmin
encourages thrombolysis and activates TGFβ. TGFβ has both atheroprotective eﬀects (inhibition of SMC migration and proliferation) and
atherogenic eﬀects (inhibition of EC migration, induction of EC cell surface adhesion molecules). (b) Under conditions of elevated plasma
Lp(a), plasminogen activation is impaired by multiple mechanisms: Lp(a) competes with plasminogen and tPA for fibrin binding (1). In
addition, Lp(a) increases expression of PAI-1 (2) and associates with SERPIN1A (3), both leading to inhibition of tPA. Finally, Lp(a) can
associate with α2-macroglobulin, a plasmin inhibitor (4). In combination, all these factors promote a prothrombotic environment.
inhibitor A1 (SERPINA1, a tPA inhibitor) [8]. Therefore,
Lp(a) can inhibit activation of plasminogen via multiple
pathways—inhibiting the association of plasminogen, fibrin
and tPA, reducing availability of tPA, increasing expression of
tPA inhibitor PAI-1, and associating with SERPINA1, which
taken together can all lead to impairment of fibrinolysis
(Figure 1(b)).
2.4. Inhibition of TGFβ Activation. One of the substrates of
plasmin is transforming growth factor beta (TGFβ) [29].
TGFβ has a variety of cellular eﬀects which can either protect
against atherosclerosis (e.g., inhibition of SMC migration
[30]) or promote atherosclerosis (e.g., inhibition of EC
migration [31] and induction of intercellular adhesion
molecule-1 (ICAM-1) expression on EC [32], summarised
in Figure 1(a)). In addition, active TGFβ can reduce
transcription of the apo(a) gene [33]. As Lp(a) has been
shown to inhibit plasminogen activation, it also prevents
activation of TGFβ leading to an increase in proliferation and
migration of cells within vessel walls [34]. This was shown to
be dependent on the apo(a) subunit since TGFβ activation
was unaﬀected by LDL alone [35]. Accordingly, studies using
aortic SMC revealed that treatment for 96 h with r-apo(a)
did not prevent secretion of latent TGFβ per se, but did
inhibit its activation through a KIV type 9 dependent eﬀect,
abrogating the antiproliferative and antimigratory capacity
of TGFβ [36]. A later study in HUVEC revealed that r-apo(a)
treatment for 72 h decreased TGFβ activity as predicted;
however, in this case it was accompanied by a 50% decrease
in total TGFβ secreted from the cell suggesting a further
mechanism(s) whereby Lp(a) may reduce the bioavailability
of TGFβ. Under those conditions, reduction in TGFβ activity
and production were dependent upon the LBS on KIV type
10 and KV, and on integrin αvβ3 [37].
3. Inflammatory Cell
Recruitment and Adhesion
One of the main mechanisms through which Lp(a) confers
its eﬀects is mediation of inflammation. Plasma Lp(a)
levels are reportedly elevated in patients suﬀering from
inflammatory diseases such as Crohn’s disease [38] and
in the microvasculature of inflammatory lesions in gall
bladder, heart, and lymph nodes [20]. Expression of Lp(a)
is increased by the proinflammatory cytokine interleukin-
6 (IL-6), through binding to multiple sites in the apo(a)
promoter [39], prompting speculation that it may act
as an acute phase reactant. In addition, Lp(a) has been
reported to carry oxidised phospholipids, promote secretion
of inflammatory cytokines, attract inflammatory cells to sites
of deposition, and encourage transendothelial migration as
described below (summarised in Figure 2).
3.1. Transportation of Oxidised Phospholipids. Lp(a) is
claimed to be an acute phase reactant, with increased circu-
lating levels being observed following myocardial infarction
[40, 41] and percutaneous coronary intervention [42]. It
is speculated that this may point to a physiological anti-
inflammatory role for Lp(a) in patients with low plasma
levels, whereby Lp(a) could bind to and remove oxidised
phospholipids from the circulation, preventing further dam-
age. Oxidised phospholipids are proinflammatory in nature
and are bound by Lp(a). Although they are often found
associated with apoB-100 [43], studies have shown that
within the Lp(a) molecule the association was dependent
on KV of the apo(a) moiety [44]. The amount of oxidised
phospholipid bound to apo(a) remained constant and was
unaﬀected by apo(a) size suggesting that it was bound to
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Figure 2: Inflammatory cell attraction and adhesion. Lp(a) encourages homing of inflammatory cells to sites of Lp(a) deposition within the
vascular wall. Circulating cells are attracted to the endothelium by inflammatory cytokines induced by Lp(a). They then bind to and migrate
through resident EC via adhesion molecules on the endothelial surface, also induced by Lp(a).
apo(a) during synthesis in the hepatocyte and was not
derived from plasma LDL [45]. Whilst this may be beneficial
in low concentrations, in patients with high plasma levels
of Lp(a) preferential binding of oxidised phospholipids
may lead to their deposition within the vessel wall, hence
promoting atherogenesis [46].
3.2. Induction of Inflammatory Cytokines. Lp(a) has been
shown to induce inflammatory cytokine expression in a
cell-type-specific manner. For example, apo(a) induced IL-
8 expression in macrophages, but not monocytes. Detailed
analysis revealed that Lp(a) induced a 12-fold increase in
IL-8 mRNA, whereas apo(a) alone was almost three times
more potent in inducing transcription. This was mirrored at
the protein level and was dependent on KV and interaction
with Gs protein receptors. IL-8 induction was not observed
by exposure to LDL or Lp(a) moieties without the apo(a)
fragment [47] confirming the essential role of the apo(a)
moiety in this process. In addition, Lp(a) also induced
expression of IL-1β, tumour necrosis factor alpha (TNF-
α), and monocyte chemoattractant protein (MCP-1) in
macrophages. Interestingly, pretreatment with 17β-estradiol
has been shown to attenuate the induction of proinflamma-
tory cytokines and also reduced macrophage migration in an
Lp(a) transgenic mouse carotid artery ligation model [48].
Hormone replacement therapy is recognised to modulate
plasma Lp(a) levels and cardiovascular risk [49], most likely
through an estrogen receptor response element within the
promoter of the apo(a) gene [50].
3.3. Chemoattraction. Through its functional eﬀects on EC,
Lp(a) can induce chemotaxis and attract monocytes via both
direct and indirect mechanisms. HUVEC treated with Lp(a)
produced MCP-1 [48] and another monocyte chemoattrac-
tant, I-309 [51]. I-309 is a CC chemokine commonly secreted
by T-lymphocytes and monocytes to attract leukocytes. LDL
alone caused a minimal and nonsignificant upregulation
of I-309; in further detailed analysis either 17K r-apo(a)
(containing all KIV types) or 6K r-apo(a) (containing KIV
types 5–10) was investigated. The 6K r-apo(a) fragment
was almost twice as eﬀective as 17K r-apo(a) in increasing
monocyte chemoattraction. The eﬀect of 6K r-apo(a) was
blocked by coincubation with I-309 siRNA or neutralising
antibody and occurred through its receptor, CCR8. This
is another example that clearly demonstrates the cell-type-
specific nature of Lp(a) signalling, as a similar study in
neutrophils showed no eﬀect [51]. It is interesting that
the smaller r-apo(a) isoform was a more potent monocyte
chemoattractant as smaller Lp(a) isoforms are known to be
associated with greater CVD risk [52].
Lp(a) has also been shown to induce monocyte chemoki-
nesis directly, independently of the presence of EC. When
monocytes were introduced into transwell chamber migra-
tion assays, Lp(a) or r-apo(a) both enhanced migration
by 400% or 300%, respectively, above basal levels. The
magnitude of response observed with Lp(a) suggested that
the LDL/apoB-100 subunit may also contribute to this
eﬀect. Lp(a) also reportedly activated pertussis-sensitive Gi-
proteins on the cell surface, activated PKC, and increased
intracellular levels of cyclic GMP, resulting in chemokinesis.
As before, neutrophils exhibited marked resistance to the
promigratory eﬀects of Lp(a) [53].
In addition to attracting monocytes, Lp(a) may also
facilitate their migration though the endothelium. In a study
designed to mimic the in vivo environment, the membranes
of migration chamber inserts were precoated with a con-
fluent layer of HUVEC. Monocytes were loaded into the
upper chamber, and the migration assay performed with
Lp(a) or r-apo(a) in the lower chamber as chemoattractants.
Significantly more monocytes migrated through the EC layer
in response to Lp(a) or r-apo(a) than control conditions, in a
manner that was dependent upon αMβ2 Mac-1 integrin [19].
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3.4. Adhesion of Inflammatory Cells to the Endothelium.
In addition to promoting monocyte migration through
an endothelial monolayer as described above, Lp(a) has
been shown to promote adhesion of monocytes by binding
through αMβ2 Mac-1 integrin, an eﬀect dependent on
the LBS of the apo(a) fragment. Adhesion was enhanced
through coincubation with homocysteine, a proathero-
genic molecule, yet interestingly pretreatment with aspirin
decreased adhesion by 30–40% [19]. Interestingly, aspirin
has been reported to lower plasma Lp(a) by reducing
transcription of the apo(a) gene [54]. Aspirin may, therefore,
modulate the perceived detrimental eﬀects of Lp(a) on
multiple levels and may be more beneficial for patients with
CVD and high circulating levels of Lp(a) than previously
thought.
In addition to binding integrins, Lp(a) has been shown
to induce adhesion molecule expression on EC. Treatment
of HCAEC with Lp(a) resulted in increased expression of
vascular cell adhesion molecule (VCAM)-1 and E-selectin.
In this case, apo(a) alone was not suﬃcient to induce
expression and yet removing apo(a) from the Lp(a) molecule
also resulted in no eﬀect. It appears that in this case,
both components of Lp(a) were essential in mediating the
response [55]. Importantly, adhesion molecule expression is
highly dependent on the source of EC; HUVEC treatment
with Lp(a) or r-apo(a) alone caused a marked increase
in ICAM-1 and yet had no eﬀect on VCAM-1 or E-
selectin expression [56]. On the other hand, Lp(a) induced
expression of all three adhesionmolecules (ICAM-1, VCAM-
1, and E-selectin) in bovine aortic endothelial cells (BAEC).
Intriguingly, in this case pretreatment with 17β-estradiol
attenuated this eﬀect suggesting an additional mode of
cardioprotection by estrogen [48]. It is clear that the source
of EC and the experimental model used require careful
consideration when interpreting data relating to Lp(a).
4. Vascular Remodelling
The capacity of vessel walls to respond and remodel to exter-
nal cues is essential for vascular adaptation to physiological
processes and also in “pathological” remodelling observed
in CVD. Endothelial dysfunction and aberrant proliferation
and migration of SMC are characteristic in the development
of atherosclerosis [57]. Lp(a) has been observed to be
deposited in atherosclerotic lesions [19] and is proposed
to mediate vascular remodelling through alterations in the
proliferative and migratory capacity of resident EC/SMC
cells as described below (summarised in Figure 3).
4.1. Proliferation of Smooth Muscle Cells. Aberrant prolifera-
tion of SMC is detrimental to the vessel, and as mentioned
earlier Lp(a) has been reported to induce SMC proliferation
via inhibition of TGFβ activation [58]. Treatment of SMC
with r-apo(a) for 24–96 h promoted an approximate 60%
increase in SMC proliferation, dependent on the LBS in
KIV type 9 [36]; however, prolonged exposure to Lp(a)
may also promote SMC proliferation via additional apo(a)-
independent mechanisms. For example, Lp(a) increased
SMC proliferation by ∼37% following 5 days of treatment,
whereas treatment with LDL alone induced proliferation
by 63% prompting the authors to speculate that as well
as inhibiting TGFβ activation, Lp(a) enhanced SMC pro-
liferation through an LDL-dependent pathway [35]. LDL
has previously been reported to increase SMC proliferation
although this observation is inconsistent and requires further
validation [59, 60].
Oxidised phospholipids are potent inducers of CVD;
the pathogenicity of LDL is greatly increased when the
molecule is oxidised [61]. The magnitude of the eﬀect
of Lp(a) as an SMC mitogen has been reported to be
increased in its oxidised state (oxLp(a)) [62]. A common
intracellular signalling pathway linked to proliferation is
extracellular signal-related kinase (ERK). Native Lp(a) was
seen to activate this pathway and induced SMC proliferation;
however, oxLp(a) caused a more robust phosphorylation of
ERK and a concomitant increase in SMC proliferation [62].
Therefore, just as the oxidative state of LDL influences its
potency as a cardiovascular risk factor, similarly the oxidative
state of Lp(a) may also influence its pathogenicity.
In addition to direct stimulation of SMC proliferation
via the apo(a) and LDL moieties and inhibition of TGFβ
activation, Lp(a) may also promote SMC proliferation
within the vessel wall by increasing expression of EC-
derived platelet-derived growth factor (PDGF), a potent
SMC mitogen. Reports have shown that oxLp(a) is capable
of inducing PDGF expression in HUVEC [63], which
would presumably further enhance SMC proliferation within
vessel walls. However, native Lp(a) appears not to induce
PDGF expression [20, 63], lending further support to the
theory that oxLp(a) is a more potent mediator of vascular
dysfunction than native Lp(a).
4.2. Proliferation of Endothelial Cells. Whilst the pathways
to Lp(a)-induced SMC proliferation are well defined, the
mechanisms of Lp(a) eﬀects on EC appear more complex.
Although Lp(a) reportedly induced a 4.5-fold increase in
HUVEC proliferation, this was considerably less than the 6-
fold induction evident in response to LDL alone suggesting
that in this case, the apoB-100/LDL component of Lp(a)
may have been more potent in mediating the proliferative
response than the apo(a) fragment [64]. Later studies util-
ising r-apo(a) and Lp(a) in HUVEC observed a comparable
increase in proliferation with either treatment, indicating
that it was the apo(a) fragment that was responsible for the
proliferative response. When EC were treated with apo(a)
alone, proliferation was dependent on the LBS in KIV type
10, KV, and integrin αvβ3. However, when the whole Lp(a)
molecule was used, the LBS was no longer an essential
requirement for the mitogenic response [37]. Although the
first study demonstrated enhanced proliferation with LDL
[64], the second reported no eﬀect [37]. These discrepant
results may be explained by diﬀerences in experimental
protocols, in which one study used serum-free culture
medium whilst in the other, cells were already stimulated to
proliferate with insulin and fibroblast growth factor (FGF)
[64]. It seems likely that LDL and growth factors such
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Figure 3: Proliferation and migration of resident vascular wall cells. Lp(a) promotes vascular remodelling by activating multiple signalling
pathways within SMC and EC. The response of the cell (e.g., proliferation, migration, or apoptosis) is dependent upon Lp(a) activated
signalling cascades that are cell-type specific and dependent upon the oxidation state of the Lp(a) molecule.
as insulin may act in a synergistic manner to influence
EC proliferation. To add a further level of complexity,
Lp(a) has been shown to increase expression of FGF-2 in
HUVEC, and the stimulatory eﬀect of Lp(a) was blunted
when inhibitors of FGF-2 or Gi-proteins were included [65];
therefore, synergy between Lp(a) and FGF-2 may also occur.
In order to validate such a suggestion, further studies could
be performed examining specifically the interplay between
apo(a), LDL-apoB-100, and whole Lp(a) in the presence and
absence of a range of other putative mitogens.
Independently of LDL, r-apo(a) has been shown to
activate several intracellular signalling cascades in HUVEC
that are linked to proliferation, for example, focal adhesion
kinase (FAK) and the mitogen-activated kinases (MAPKs)
p38, p42/44 ERK and p-54 c-Jun N-terminal kinase (JNK).
However, all these phosphorylation events were integrin αvβ3
dependent [37]. Again, to further clarify the importance of
component parts of the Lp(a) molecule, further signalling
studies could be performed to address this question.
Themitogenic properties of Lp(a) appear to be consistent
between cell types. In mesangial cells, Lp(a) (5 μg/mL)
induced a small yet significant enhancement of DNA synthe-
sis that was only evident in serum-free cultures, suggesting
that increased proliferation was not due to an inhibitory
eﬀect of Lp(a) on TGFβ activation and was more likely to be
dependent upon the apoB-100/LDL fragment [66]. Indeed,
increased EC proliferation has been observed with similar
concentrations of LDL [67]. Another study in mesangial
cells had reported reduced DNA synthesis on exposure to a
comparable concentration of Lp(a) [67]; however, this study
used low concentrations (0.5%) of serum in the cultures that
potentially masked any subtle changes in DNA synthesis.
In spite of published evidence that Lp(a) is mitogenic,
there have been a number of studies suggesting, conversely,
that oxLp(a) may promote apoptosis. The reported pro-
apoptotic eﬀect of oxLp(a) on HUVEC was mediated as
a result of oxidative stress and was counteracted by co-
incubation with superoxide dismutase and catalase. Intrigu-
ingly, this particular study showed that native Lp(a) also
exhibited mild proapoptotic properties; however, this was
significantly less so than apoptosis induced by oxLp(a) [68].
A recent report demonstrated that oxLp(a)/apo(a) was able
to provoke apoptosis in macrophages that were undergo-
ing endoplasmic reticulum stress. This was dependent on
oxidised phospholipids carried by the apo(a) molecule and
involved apoptotic signalling via CD36-Toll-like receptor 2
(TLR2) and generation of reactive oxygen species (ROS)
[69]. It is interesting that the same concentration of Lp(a)
used in two separate studies induced opposing eﬀects of
apoptosis [68] and proliferation [64]. It is possible that
alternative signalling events occur in EC, whereby Lp(a)
stimulates proliferation via the ERK pathway, and apoptosis
through ROS generation, depending upon the environment
of the EC, thus contributing to dysfunction at multiple levels.
4.3. Migration of Smooth Muscle and Endothelial Cells. In
addition to altered proliferation, aberrant migration of
SMC and EC also contributes significantly to cardiovascular
pathologies. Enhanced migration of SMC treated with r-
apo(a) was observed over a period of 24–96 h; the increased
speed of SMC migration being dependent on KIV type 9
[36]. Increased migration in HUVEC has also been demon-
strated, whereby exposure to r-apo(a) or Lp(a) directly
enhanced migration in a scratch wound model. However, in
these cells, the promigratory eﬀect was dependent on the LBS
in KIV type 10, KV, and integrin αvβ3. In the case of Lp(a),
migration was not prevented by inhibiting the LBS proposing
an involvement of the LDL/apoB-100 moiety [37]. However,
Lp(a) was more potent than LDL in promoting HUVEC
migration suggesting that it is the apo(a) fragment playing
the major role with minimal contribution from LDL/apoB-
100 [65].
The molecular mechanisms that underlie cellular migra-
tion are complex but result in coordinated rearrangement
of the actin cytoskeleton and increased formation of f-actin
stress fibres to promote cell motility. Accordingly, apo(a)
has been reported to influence stress fibre formation. When
either HUVECs or HCAECs were incubated with concentra-
tions of r-apo(a) as low as 25 nM, there was a notable increase
in the appearance of stress fibres, an eﬀect reproduced by
Lp(a). However, incubation with plasminogen or LDL had
no eﬀect, demonstrating the apo(a)-dependency of stress
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Table 1: Lp(a) subunits responsible for cellular eﬀects.
Process LDL-apoB-100 Apo(a) Region References
Thrombosis
(i) Platelet aggregation
√ √
[11–17]
(ii) ↑ tissue factor pathway — √ [19–21]
(iii) ↓ plasminogen activation — √ KIV type 10, KV [8, 20, 23–28]
(iv) ↓ TGFβ activation × √ KIV type 9 [34–37]
(v) ↓ TGFβ production — √ KIV type 10, KV [37]
Inflammation
(i) Oxidised phospholipids × √ KV [44–46]
(ii) ↑monocyte migration √ √ [19, 51, 53]
(iii) ↑monocyte adhesion × √ KIV type 10 [19]
Vascular remodelling
(i) ↑ SMC proliferation √ √ KIV type 9 [35, 36, 58, 62]
(ii) ↑ SMC migration — √ KIV type 9 [36]
(iii) ↑ EC proliferation √ √ KIV type 10, KV [37, 64, 65]
(iv) ↑ EC migration √ √ KIV type 10, KV [37, 65]
(v) ↑ EC contraction — √ KIV type 10 [70]
For detailed information, see main body of text and highlighted references. Key:
√
= positive for eﬀect, × = negative for eﬀect, — = not tested.
fibre formation. The RhoA/Rho kinase (ROCK) pathway is
a key modulator of f-actin cytoskeleton arrangement [71],
and its central role in mediating the eﬀect of apo(a) was
demonstrated by abolition with ROCK inhibitors [72].
In addition to increasing stress fibre formation, r-
apo(a) has been reported to increase endothelial perme-
ability by inducing cell contraction [70], an eﬀect that
would facilitate transendothelial migration of monocytes
as previously observed in vitro [19]. Detailed examination
of the underlying mechanism in HUVEC revealed that
contraction was dependent on the strong LBS within KIV
type 10 [72], enhancing stress fibre formation and cell
contraction through phosphorylation of myosin light chain
(MLC) via two mechanisms. Firstly, by increasing MLC
kinase (MLCK) activity, and secondly by increasing myosin
phosphatase target subunit 1 (MYPT1) activity (an inhibitor
of MLC phosphatase) thereby promoting phosphorylation
and activity of MLC [70]. Apo(a) has been shown to activate
RhoA in HUVEC [72] and accordingly phosphorylation of
MLC was dependent on the activation of RhoA and ROCK
[70].
Alterations in intracellular calcium levels ([Ca2+]i) are
known to have a significant impact on many cellular
functions including migration [73]. However, the influence
of r-apo(a) on [Ca2+]i is controversial and is reported to vary
according to cell type and species. For example, one report
demonstrated that treatment of HUVECs with r-apo(a) did
not alter Ca2+ homeostasis; however, some of the recognised
eﬀects of r-apo(a) were mediated via Ca2+-sensitive proteins
such as MLCK [72]. Intriguingly, another report revealed
that when a variety of human EC (coronary artery, aortic, or
heartmicrovascular) were treated with Lp(a), a proportion of
cells within any cell population responded whilst others did
not [55]. Furthermore, treatment of human mesangial cells
with Lp(a) caused a transient increase in [Ca2+]i that was
dependent on pertussis-sensitive Gi proteins [66]. Clearly,
the mechanisms via which Lp(a) may or may not aﬀect Ca2+-
dependent cellular eﬀects require extensive further study
before any firm interpretations can be drawn.
5. Conclusions
In this paper, we have evaluated published evidence that
supports a role of Lp(a) as a proatherogenic CVD risk factor.
It is clear that Lp(a) is capable of a broad spectrum of
functional eﬀects within the cardiovascular system, through
both its LDL/apoB-100 moiety and apo(a) chain (Table 1).
Such eﬀects are potentially detrimental to cardiovascular
health, contributing to CVD progression via activation of
a diverse range of cell surface receptors and signalling
pathways, principally:
(1) modulation of platelet aggregation (αIIbβ3),
(2) reduction in fibrinolysis (αMβ2, αvβ3, NFκB, PKC),
(3) recruitment of inflammatory cells (αMβ2, E-selectin,
ICAM-1, VCAM-1, IL-1β, IL-8, PKC),
(4) induction of vascular remodelling (αvβ3, Ca2+,
MAPK, RhoA, ROS).
A cognate receptor for Lp(a) remains elusive and indeed
may not exist. However, the capacity of Lp(a) to activate
a diverse range of proteins and receptors suggests that it
is unlikely to activate a single receptor that could yield a
single therapeutic target. A combination of therapies may,
therefore, oﬀer alternative benefits in reducing cardiovas-
cular damage induced by Lp(a). For example, treatment
with aspirin to reduce apo(a) gene expression in addition
to using statins to inhibit RhoA-dependent functional eﬀects
on EC and SMC may be of value. Indeed, improved bypass
patency rates in patients with high plasma Lp(a) receiving
statin therapy compared to those not taking statins have
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been reported [74]. Over recent decades robust cholesterol
management through statin therapy has had a profound
eﬀect on cardiovascular protection, although a similar
management for plasma Lp(a) seems unlikely at present.
Dissecting the signalling mechanisms that Lp(a) exploits in
cardiovascular cells is therefore key to identifying suitable
targets for therapeutic intervention in the short term.
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